RhumbLine Advisers
ADXN

RhumbLine Advisers’s Addex Therapeutics ADXN Stock Holding History

RhumbLine Advisers’s Portfolio ADXN Stock Details ADXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$450 Hold
72
– – ﹤0.01% 4015
2025
Q4 		$554 Hold
72
– – ﹤0.01% 4053
2025
Q3 		$655 Hold
72
– – ﹤0.01% 4049
2025
Q2 		$637 Hold
72
– – ﹤0.01% 4059
2025
Q1 		$528 Sell
72
-35
-33% -$271 ﹤0.01% 4053
2024
Q4 		$749 Buy
107
+72
+206% +$656 ﹤0.01% 4085
2024
Q3 		$337 Buy
+35
New +$312 ﹤0.01% 4135

Other funds holding ADXN

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

RhumbLine Advisers's ADXN Position: Q1 2026 in Review

RhumbLine Advisers held its Addex Therapeutics (ADXN) position steady in Q1 2026 at 72 shares worth $450. The position accounts for ﹤0.01% of the portfolio, ranked #4015.

RhumbLine Advisers first reported a position in ADXN in Q3 2024 and has held it in 7 quarters since. The position peaked at $749 in Q4 2024. 4 funds tracked by Wall St. Rank hold ADXN as of Q1 2026.

  • RhumbLine Advisers held 72 shares of Addex Therapeutics worth $450 as of Q1 2026.
  • RhumbLine Advisers left its Addex Therapeutics share count unchanged in Q1 2026.
  • Addex Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #4015 holding.
  • RhumbLine Advisers first reported a position in Addex Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • RhumbLine Advisers's Addex Therapeutics position peaked at $749 in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Addex Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.